UMB Bank’s Emergent Biosolutions EBS Stock Holding History

UMB Bank’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-64	Closed	-$2K	–	1804
2022 Q2	$2K	Hold	64	–	–	﹤0.01%	1727
2022 Q1	$3K	Hold	64	–	–	﹤0.01%	1747
2021 Q4	$3K	Buy	+64	New	+$2.9K	﹤0.01%	1735

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

UMB Bank's EBS Position: Q3 2022 in Review

UMB Bank sold out of Emergent Biosolutions (EBS) in Q3 2022, closing a stake of 64 shares — an estimated $2K sold.

UMB Bank first reported a position in EBS in Q4 2021 and held it in 3 quarters. The position peaked at $3K in Q1 2022. 211 funds tracked by Wall St. Rank hold EBS as of Q3 2022.

UMB Bank reported no remaining Emergent Biosolutions position as of Q3 2022 after selling out during the quarter.
UMB Bank sold 64 Emergent Biosolutions shares in Q3 2022, an estimated $2K.
UMB Bank first reported a position in Emergent Biosolutions in Q4 2021 and held it in 3 quarters.
UMB Bank's Emergent Biosolutions position peaked at $3K in Q1 2022.
211 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2022.

Based on UMB Bank's 13F filing for Q3 2022, filed 13 Oct 2022.